YU10101A - Prolekovi inhibitori proton pumpe - Google Patents

Prolekovi inhibitori proton pumpe

Info

Publication number
YU10101A
YU10101A YU10101A YU10101A YU10101A YU 10101 A YU10101 A YU 10101A YU 10101 A YU10101 A YU 10101A YU 10101 A YU10101 A YU 10101A YU 10101 A YU10101 A YU 10101A
Authority
YU
Yugoslavia
Prior art keywords
proton pump
prodrugs
pump inhibitor
inhibitor drugs
benzimidazole
Prior art date
Application number
YU10101A
Other languages
English (en)
Inventor
Michael Garst
George Sachs
Jai Moo Shin
Original Assignee
Partnership Of Michael E. Garst George Sachs And Jai Moo Shin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/131,481 external-priority patent/US6093734A/en
Application filed by Partnership Of Michael E. Garst George Sachs And Jai Moo Shin filed Critical Partnership Of Michael E. Garst George Sachs And Jai Moo Shin
Publication of YU10101A publication Critical patent/YU10101A/sh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Abstract

Prolekovi piridil, metil, sulfinil, benzimidazol, tipa lekova inhibitora proton pumpe imaju hidrolizabilnu sulfinil ili arilsulfonil grupu pričvršćenu na azot benzimidazola, ili sadrže grupu koja formira Mannich baze sa benzimidazol azotom. Prolekovi pronalaska hidrolizuju u fiziološkim uslovima da bi obezbedili inhibitore proton pumpe sa poluživotom koji se može meriti u časovima, i sposobni su da obezbede ustaljene plazma koncentracije lekova inhibitora proton pumpe duže vremena nego lekovi koji su danas u upotrebi. Generisanje lekova inhibitora proton pumpe iz prolekova pronalaska u fiziološkim uslovima omogućuje efektivniji tretman nekoliko bolesti i stanja izazvanih sekrecijom želudačne kiseline.[Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable sulfinyl or arylsulfonyl group attached to the benzimidazole nitrogen, or include a group that forms a i(Mannich) base with the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under physiological conditions to provide the proton pump inhibitors with a half life measurable in hours, and are capable of providing sustained plasma concentrations of the proton pump inhibitor drugs for longer time than presently used drugs. The generation of the proton pump inhibitor drugs from the prodrugs of the invention under physiological conditions allows for more effective treatment of several diseases and conditions caused by gastric acid secretion.
YU10101A 1998-08-10 1999-08-09 Prolekovi inhibitori proton pumpe YU10101A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/131,481 US6093734A (en) 1998-08-10 1998-08-10 Prodrugs of proton pump inhibitors
US36438199A 1999-07-29 1999-07-29

Publications (1)

Publication Number Publication Date
YU10101A true YU10101A (sh) 2003-10-31

Family

ID=26829517

Family Applications (1)

Application Number Title Priority Date Filing Date
YU10101A YU10101A (sh) 1998-08-10 1999-08-09 Prolekovi inhibitori proton pumpe

Country Status (28)

Country Link
US (1) US6559167B1 (sh)
EP (1) EP1105387B1 (sh)
JP (1) JP4346243B2 (sh)
KR (1) KR100472126B1 (sh)
CN (1) CN100396675C (sh)
AT (1) ATE231857T1 (sh)
AU (1) AU752292B2 (sh)
BG (1) BG64870B1 (sh)
BR (1) BR9912937A (sh)
CA (1) CA2338311C (sh)
DE (1) DE69905171T2 (sh)
DK (1) DK1105387T3 (sh)
ES (1) ES2192394T3 (sh)
FI (1) FI20010248A (sh)
HK (1) HK1035368A1 (sh)
HR (1) HRP20010106A2 (sh)
HU (1) HUP0103464A3 (sh)
ID (1) ID28273A (sh)
IL (2) IL141083A0 (sh)
IS (1) IS5826A (sh)
MX (1) MXPA01001464A (sh)
NO (1) NO322490B1 (sh)
NZ (1) NZ510180A (sh)
PL (1) PL346000A1 (sh)
TR (1) TR200100431T2 (sh)
UA (1) UA67788C2 (sh)
WO (1) WO2000009498A1 (sh)
YU (1) YU10101A (sh)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002342917A1 (en) * 2001-11-19 2003-06-10 Altana Pharma Ag Reversible proton pump inhibitors for the treatment of airway disorders
NZ538221A (en) 2002-07-19 2006-11-30 Univ California Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor for treating gastrointestinal inflammatory diseases
JP2006188432A (ja) * 2003-02-25 2006-07-20 Zeria Pharmaceut Co Ltd 四環系スルフェンアミド化合物
EP1644352A1 (en) * 2003-07-15 2006-04-12 Allergan, Inc. Process for preparing isomerically pure prodrugs of proton pump inhibitors
KR20060118421A (ko) * 2003-08-29 2006-11-23 다이노젠 파마세우티컬스, 인코포레이티드 위장 운동 장애의 치료에 유용한 조성물
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20060241037A1 (en) * 2003-10-03 2006-10-26 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump ihhibitor prodrugs
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
AU2005216862A1 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Compositions comprising prodrugs of proton pump inhibitors
US20070161679A1 (en) * 2004-02-18 2007-07-12 Allergan, Inc. Method and compositions for the intravenous administration of compounds related to proton pump inhibitors
MXPA06011820A (es) * 2004-04-16 2006-12-15 Santarus Inc Combinacion de inhibidor de bomba de proton, agente regulador del ph y agente procinetico.
ES2327926T3 (es) * 2004-04-28 2009-11-05 Hetero Drugs Limited Procedimiento de preparacion de compuestos de piridinilmetil-1h-benzimidazol en forma de enantiomeros simples o enantiomericamente enriquecidos.
EP1748998B1 (en) * 2004-05-28 2010-01-27 Hetero Drugs Limited A novel stereoselective synthesis of benzimidazole sulfoxides
JP2008503470A (ja) * 2004-06-17 2008-02-07 ワイス ゴナドトロピン放出ホルモン受容体アンタゴニストの製造法
BRPI0512261A (pt) * 2004-06-17 2008-02-26 Wyeth Corp antagonistas de receptor de hormÈnio liberador de gonadotropina
EP1796673A2 (en) * 2004-09-23 2007-06-20 Reddy US Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
CA2587853A1 (en) * 2004-11-23 2006-06-01 Wyeth Gonadotropin releasing hormone receptor antagonists
US7582634B2 (en) * 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) * 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) * 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US20060189619A1 (en) * 2005-02-24 2006-08-24 Wyeth 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds
US20070015782A1 (en) 2005-04-15 2007-01-18 Eisai Co., Ltd. Benzimidazole compound
US9040564B2 (en) 2005-04-28 2015-05-26 Eisai R&D Management Co., Ltd. Stabilized composition
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) * 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
JPWO2006134877A1 (ja) * 2005-06-13 2009-01-08 武田薬品工業株式会社 注射剤
WO2007073301A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Benzoimidazole derivatives as prodrugs of proton pump inhibitors
US20100317689A1 (en) * 2006-09-19 2010-12-16 Garst Michael E Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
WO2008036211A1 (en) * 2006-09-19 2008-03-27 Alevium Pharmaceuticals, Inc. Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
CN101497622B (zh) * 2008-01-30 2011-04-27 山东轩竹医药科技有限公司 吡啶甲基亚磺酰基咪唑并吡啶衍生物
CA2716367C (en) 2008-02-20 2015-05-26 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
UA100192C2 (en) * 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
EP2921479B1 (en) * 2012-11-19 2017-02-01 Jiangsu Hansoh Pharmaceutical Co., Ltd. Pyrrole sulfonamide derivative, preparation method for same, and medical application thereof
WO2014133059A1 (ja) 2013-02-28 2014-09-04 武田薬品工業株式会社 スルホニルクロライド化合物の製造法
MA54133B1 (fr) 2018-03-08 2022-01-31 Incyte Corp Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
JP2023527155A (ja) 2020-05-20 2023-06-27 エフ. ホフマン-ラ ロシュ アーゲー 質量分析のための試薬

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) * 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
SE8300736D0 (sv) * 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
IL76839A (en) * 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
SE8505112D0 (sv) * 1985-10-29 1985-10-29 Haessle Ab Novel pharmacological compounds
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
WO1991019712A1 (en) * 1990-06-20 1991-12-26 Aktiebolaget Astra Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
US5945425A (en) * 1994-04-29 1999-08-31 G.D. Searle & Co. Method of using (H+ /K+)ATPase inhibitors as antiviral agents
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
SE9602442D0 (sv) 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals

Also Published As

Publication number Publication date
ES2192394T3 (es) 2003-10-01
BG105191A (en) 2001-12-29
MXPA01001464A (es) 2002-05-08
JP2003534232A (ja) 2003-11-18
TR200100431T2 (tr) 2001-06-21
BR9912937A (pt) 2001-05-08
JP4346243B2 (ja) 2009-10-21
IL141083A0 (en) 2002-02-10
KR100472126B1 (ko) 2005-03-08
CN1312806A (zh) 2001-09-12
NO20010693L (no) 2001-03-05
EP1105387A1 (en) 2001-06-13
IL141083A (en) 2006-07-05
CA2338311A1 (en) 2000-02-24
HUP0103464A2 (hu) 2002-02-28
ATE231857T1 (de) 2003-02-15
WO2000009498A1 (en) 2000-02-24
ID28273A (id) 2001-05-10
CA2338311C (en) 2007-01-23
UA67788C2 (uk) 2004-07-15
NZ510180A (en) 2002-11-26
NO322490B1 (no) 2006-10-09
HK1035368A1 (en) 2001-11-23
KR20010103566A (ko) 2001-11-23
PL346000A1 (en) 2002-01-14
NO20010693D0 (no) 2001-02-09
CN100396675C (zh) 2008-06-25
AU752292B2 (en) 2002-09-12
DE69905171D1 (de) 2003-03-06
EP1105387B1 (en) 2003-01-29
HRP20010106A2 (en) 2002-02-28
HUP0103464A3 (en) 2002-11-28
DE69905171T2 (de) 2003-11-20
DK1105387T3 (da) 2003-06-23
IS5826A (is) 2001-01-29
FI20010248A (fi) 2001-02-09
AU5551899A (en) 2000-03-06
BG64870B1 (bg) 2006-07-31
US6559167B1 (en) 2003-05-06

Similar Documents

Publication Publication Date Title
YU10101A (sh) Prolekovi inhibitori proton pumpe
TR200103493T2 (tr) Metaloproteaz önleyicileri
NO20051892L (no) Ny forbindelse
PA8509301A1 (es) Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en enfermedades inflamatorias, autoinmunes y respiratorias
EA200400966A1 (ru) Новые лекарственные формы замещенного бензимидазола и способ их применения
ATE211931T1 (de) Topoisomerase inhibitoren zur restenose- prevention
NO20051893L (no) Ny forbindelse
SE9801526D0 (sv) New compounds
TR200201144T2 (tr) NFKB aktivitesinin modülasyonu için ikame edilmiş indoller
NO20052487L (no) 1-(4-benzyl-piperazin-1-yl)-3-fenyl-propenonderivater.
NO20014046L (no) Gabapentinderivater for forhindring og behandling av visceral smerte
IN2005KO00312A (sh)
TW200510311A (en) CCr8 inhibitors
DK0696456T3 (da) Kombination af nekrosefremkaldende stoffer med stoffer, som aktiveres af nekroser, til selektiv behandling af tumorer og betændelsessygdomme
ES2191754T3 (es) Fenil-dihidrobenzofuranos.
ATE323695T1 (de) Benzimidazolderivative und ihre verwendung als prodrugs für protonenpumpenhemmer
IT1319202B1 (it) Farmaci per le malattie a base infiammatoria.
DE59610031D1 (de) Cyclohexyldihydrobenzofurane
NO20016201L (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
SE9802794D0 (sv) New compounds
SE9802793D0 (sv) New compounds
AR028641A1 (es) MÉTODOS PARA LA PREVENCION DE uLCERAS Y MEJORA DE LA PERFORMANCE FISIOLoGICA
DE60321025D1 (de) Verwendung von tenatoprazol zur behandlung von gastroösophogalem reflux
YU30602A (sh) Primena 2-amino-3,4-dihidro-hinazolina za proizvodnju leka za lečenje ili profilaksu bolesti koje su prouzrokovane ishemičnim stanjima
PT1220844E (pt) Derivados de benzimidazole substituidos como arilssulfonamida e sua utilizacao como inibidores de triptase